Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07229352

Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses

The aim of this study is evaluate and compare the mobility performance of children in daily activities while wearing single vision spectacle lenses (control) versus myopia control spectacle lenses (test).

Recruiting

Interested in participating?

Request Info

Key information

Age range

6 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Midwestern University Arizona College of Optometry

Glendale, Arizona, 85308, United States

Location status: Recruiting

Location contact

Javier Gantes-Nunez

CONTACT

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

A participant is eligible for inclusion in the study if they meet the following criteria:

  • Are between the ages of 6 and 12 years of age (inclusive) at the time of informed consent/assent.
  • Can achieve a corrected visual acuity of 20/20 best-corrected (or equivalent logMAR).
  • Have undergone a self-reported oculo-visual examination within the past two years.
  • Have no active ocular disease.
  • Are willing and able to adhere to instructions, study procedures, and maintain the appointment schedule.
  • Have not previously worn or participated in myopia control contact lenses for more than one month and are not currently undergoing any form of myopia control treatment.
  • The subject's parent(s) or legal guardian(s) must read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.

Exclusion criteria

A participant will be excluded from the study if they meet any of the following conditions:

  • Have any systemic disease that affects ocular health.
  • Are currently using or have used, within the past 7 days, any systemic or topical medications that may impact ocular health.
  • Are currently using or have used any topical ophthalmic agents with anti-muscarinic properties within 7 days prior to enrollment or at any point during the study. This includes, but is not limited to, atropine, scopolamine, pirenzepine, tropicamide, cyclopentolate, and homatropine.
  • Have used any oral agents with anti-muscarinic properties for a chronic period (2 months or more) or short-term (within 7 days prior to enrollment). This includes, but is not limited to, gastrointestinal anti-spasmodic medications containing atropine, hyoscyamine, and dicyclomine.
  • Have known developmental delays.
  • Have participated in another clinical study in the last 7 days

Treatment and study plan

Novel spectacle lens design

Device

Use of lenses may reduce the rate of progression of juvenile myopia

Spectacle lenses

Device

Use of lenses may reduce the rate of progression of juvenile myopia

Primary outcomes

  1. Reaction time: the time elapsed between the appearance or activation of a visual stimulus and the initiation of the participant's physical response

    Time frame: 2 months

  2. Movement time: the time taken to complete the motor response after it has been initiated.

    Time frame: 2 months

  3. Response accuracy: the correctness of the participant's response to each visual stimulus, measured by the number or percentage of correctly identified or responded-to stimuli.

    Time frame: 2 months

Secondary outcomes

  1. Gait cycle events, such as initial foot contact with the ground and toe-off. It will be used to assess whether the type of eyewear affects natural gait patterns or mobility during peripheral vision tasks.

    Time frame: 2 months

Study contacts

Contact information is provided by the study sponsor or research team.

Jennifer Hill

CONTACT

[email protected]

6783614877

Sponsors and collaborators

Lead sponsor

SightGlass Vision, Inc.

Industry

Registry information

Official study title

Mobility Performance in Daily Activities Among Children Wearing Single Vision and Myopia Control Spectacle Lenses

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Nov 17, 2025
Registry last updated
Apr 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.